Evidence map›Paper›PMID 34982369›Full record

Trial reportHepatology international2022

GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.

Wei-Ting Chen, Shi-Ming Lin, Wei-Chen Lee, Ting-Jung Wu, Chen-Chun Lin, Chien-Heng Shen, Ming-Ling Chang, Chih-Lang Lin, Chau-Ting Yeh

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02504983 (Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02504983 phase4unknown statusnot on this map

Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma

TypeinterventionalSponsorChang Gung Memorial HospitalRan2015 to 2021Enrolled200ConditionsHepatocellular CarcinomaArmssorafenib, TACE
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wei-Ting ChenLiver Research Center, Linko Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Linkou Branch, 5, Fu-Shin Street, Taoyuan, 333, Taiwan.
Shi-Ming LinLiver Research Center, Linko Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Linkou Branch, 5, Fu-Shin Street, Taoyuan, 333, Taiwan.
Wei-Chen LeeDivision of Liver and Transplantation Surgery, Linko Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Ting-Jung WuDivision of Liver and Transplantation Surgery, Linko Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Chen-Chun LinLiver Research Center, Linko Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Linkou Branch, 5, Fu-Shin Street, Taoyuan, 333, Taiwan.
Chien-Heng ShenDepartment of Gastroenterology and Hepatology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan.
Ming-Ling ChangLiver Research Center, Linko Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Linkou Branch, 5, Fu-Shin Street, Taoyuan, 333, Taiwan.
Chih-Lang LinDepartment of Gastroenterology and Hepatology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Chau-Ting YehLiver Research Center, Linko Chang Gung Memorial Hospital, Chang Gung Memorial Hospital, Linkou Branch, 5, Fu-Shin Street, Taoyuan, 333, Taiwan. chautingy@gmail.com.ORCID http://orcid.org/0000-0001-7376-275X

Funding

Chang Gung Memorial Hospital, Linkou CMRPG3K0641Chang Gung Memorial Hospital, Linkou CMRPG3K1401Chang Gung Memorial Hospital, Linkou CPRPG3E0013
6 · The paper itself

Abstract

backgroundGALNT14-rs9679162 "TT" genotype is associated with favorable clinical outcomes in hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE). We investigated whether patients with GALNT14-rs9679162 "non-TT" unfavorable genotype benefited from chemoembolization plus sorafenib combination therapy.

methodsIntermediate stage HCC patients were recruited for GALNT14-rs9679162 genotyping before TACE. Patients with "TT" genotype received only TACE, labeled as TT (TACE) group. Patients with "non-TT" genotype ("GG" or "GT") were randomized to receive either TACE alone, labeled as Non-TT (TACE) group, or TACE plus sorafenib, labeled as Non-TT (TACE + Sora) group. The latter group received sorafenib 400 mg daily plus TACE.

resultsFrom October 2015 to April 2019, 103 HCC patients scheduled to receive chemoembolization were screened. Of them, 84 met inclusion criteria and were assigned to TT (TACE) (n = 25), Non-TT (TACE) (n = 30) and Non-TT (TACE + Sora) (n = 29) groups according to their GALNT14 genotypes. Repeated TACE sessions were performed on-demand and patients were followed until November 2020. It was found that TT (TACE) and Non-TT (TACE + Sora) patients had shorter time-to-complete response compared with that in Non-TT (TACE) patients (p < 0.001 and 0.009, respectively). These two groups also had longer time-to-TACE progression (p < 0.001 and 0.006, respectively) and longer progression-free survival (p = 0.001 and 0.021, respectively). However, TT (TACE) patients harbored longer overall survival compared with those in non-TT (TACE + Sora) and non-TT (TACE) patients (p = 0.028, < 0.001, respectively).

conclusionCombination of sorafenib and TACE for "non-TT" patients partially overcame the genetic disadvantage on treatment outcomes in terms of time-to-complete response, time-to-TACE progression and progression-free survival.

trial registrationClinicalTrials.gov NCT02504983.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsCombined Modality TherapyGenotypeHumansNiacinamidePhenylurea CompoundsSorafenibTreatment OutcomeAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenibAngiogenesisBarcelona clinic liver cancer stageBiomarkerComplete responseLiver cancerOverall survivalPolypeptide N-acetylgalactosaminyltransferase 14Progression-free survivalSingle-nucleotide polymorphismTargeted drug

Identifiers

PMID34982369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.